September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to all major antiplatelet therapies. Terms of the transaction were not disclosed.
ITC develops, manufactures and markets the Hemochron product line, a market-leading POC system used to measure clotting activity for patients undergoing anticoagulation therapy. Accumetrics develops, manufactures and markets the VerifyNow product line, a market-leading POC system used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.
"ITC has a history of innovation and leadership in point-of-care coagulation testing, and Accumetrics is a pioneer and leader in point-of-care platelet function testing," said John Sperzel, CEO of ITC. "The combination of ITC's Hemochron and Accumetrics' VerifyNow product lines creates a leading hospital-based POC cardiovascular diagnostics business."
"Accumetrics has played a leading role in the development of the antiplatelet monitoring market. The performance of the VerifyNow system has been demonstrated in numerous clinical studies," said Accumetrics CEO Timothy I. Still. "I am confident that combining Accumetrics with ITC provides the best opportunity to accelerate the global adoption of the VerifyNow system."
Sperzel will serve as CEO of the combined company and Greg Tibbitts, CFO of Accumetrics, will serve as CFO of the combined company. Now that the transaction has closed, the process of integrating the ITC and Accumetrics businesses will begin immediately and the leadership teams will work closely to ensure a seamless transition for customers.
The combined company will assume a new name, Accriva Diagnostics, and its corporate headquarters will be established in San Diego.
For more information: www.itcmed.com, www.accumetrics.com